Interferon add-on therapy increased clinical cure significantly for interferon-experienced chronic hepatitis B patients with low HBsAg
Currently, interferon add-on therapy brings hope for clinical cure of chronic hepatitis B patients with low HBsAg. However, in clinical practice patients with poor responses to their first interferon therapy were often switched to nucleos(t)ide analog therapy and then labeled as unsuitable patients...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-09-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2022.997608/full |
| _version_ | 1798002334572216320 |
|---|---|
| author | Xiaoan Yang Xiaoan Yang Ka Zhang Ka Zhang Qihuan Xu Qihuan Xu Xin Shu Xin Shu Zhishuo Mo Zhishuo Mo Dongying Xie Dongying Xie Zhiliang Gao Zhiliang Gao Hong Deng Hong Deng |
| author_facet | Xiaoan Yang Xiaoan Yang Ka Zhang Ka Zhang Qihuan Xu Qihuan Xu Xin Shu Xin Shu Zhishuo Mo Zhishuo Mo Dongying Xie Dongying Xie Zhiliang Gao Zhiliang Gao Hong Deng Hong Deng |
| author_sort | Xiaoan Yang |
| collection | DOAJ |
| description | Currently, interferon add-on therapy brings hope for clinical cure of chronic hepatitis B patients with low HBsAg. However, in clinical practice patients with poor responses to their first interferon therapy were often switched to nucleos(t)ide analog therapy and then labeled as unsuitable patients for interferon therapy. Even if their HBsAg levels dropped to a low level, they were reluctant or not recommended to take interferon again, which caused them to miss out on interferon add-on therapy and clinical cure. Therefore, it is urgent to elucidate the effectiveness of interferon add-on therapy to get clinical cure for these interferon-experienced patients with low HBsAg. The purpose of this study was to investigate whether interferon-experienced patients could achieve the same HBsAg clearance and HBsAg seroconversion rates as interferon-naive patients. Also, the associated factor of HBsAg clearance and seroconversion were aimed to be clarified. 292 patients, including 85 interferon-experienced patients, were enrolled with HBsAg< 1500 IU/ml, HBeAg negative and HBV-DNA negative. And then, peg-interferon α-2b add-on therapy was performed. The results showed that the week 48 HBsAg clearance and seroconversion rates of all patients were 29.8% and 22.0%. There was no statistically significant difference between interferon-experienced and interferon-naive patients in week 48 HBsAg clearance and seroconversion rates, suggesting satisfactory clinical cure of the interferon add-on therapy for interferon-experienced patients. The age, baseline HBsAg, and week 12 HBsAg were negative correlated factors for week 48 HBsAg clearance and seroconversion. Furthermore, the age, baseline HBsAg and week 12 HBsAg for predicting the week 48 HBsAg clearance were cut off at 40.5 years, at 152.0 IU/ml and at 34.99 IU/ml, and for predicting seroconversion were cut off at 40.5 years, at 181.9 IU/ml and at 34.99 IU/ml, correspondingly. Significantly, interferon-experienced patients with low HBsAg were suggested with interferon add-on therapy to achieve clinical cure as soon as possible. This research provided evidences and cut-offs for the interferon add-on therapy against chronic hepatitis B. |
| first_indexed | 2024-04-11T11:50:29Z |
| format | Article |
| id | doaj.art-03bcf6503d81441aa48e23ee4c1ee398 |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-04-11T11:50:29Z |
| publishDate | 2022-09-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-03bcf6503d81441aa48e23ee4c1ee3982022-12-22T04:25:23ZengFrontiers Media S.A.Frontiers in Immunology1664-32242022-09-011310.3389/fimmu.2022.997608997608Interferon add-on therapy increased clinical cure significantly for interferon-experienced chronic hepatitis B patients with low HBsAgXiaoan Yang0Xiaoan Yang1Ka Zhang2Ka Zhang3Qihuan Xu4Qihuan Xu5Xin Shu6Xin Shu7Zhishuo Mo8Zhishuo Mo9Dongying Xie10Dongying Xie11Zhiliang Gao12Zhiliang Gao13Hong Deng14Hong Deng15Department of Infectious Diseases, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, ChinaGuangdong Provincial Key Laboratory of Liver Disease Research, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, ChinaDepartment of Infectious Diseases, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, ChinaGuangdong Provincial Key Laboratory of Liver Disease Research, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, ChinaDepartment of Infectious Diseases, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, ChinaGuangdong Provincial Key Laboratory of Liver Disease Research, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, ChinaDepartment of Infectious Diseases, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, ChinaGuangdong Provincial Key Laboratory of Liver Disease Research, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, ChinaDepartment of Infectious Diseases, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, ChinaGuangdong Provincial Key Laboratory of Liver Disease Research, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, ChinaDepartment of Infectious Diseases, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, ChinaGuangdong Provincial Key Laboratory of Liver Disease Research, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, ChinaDepartment of Infectious Diseases, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, ChinaGuangdong Provincial Key Laboratory of Liver Disease Research, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, ChinaDepartment of Infectious Diseases, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, ChinaGuangdong Provincial Key Laboratory of Liver Disease Research, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, ChinaCurrently, interferon add-on therapy brings hope for clinical cure of chronic hepatitis B patients with low HBsAg. However, in clinical practice patients with poor responses to their first interferon therapy were often switched to nucleos(t)ide analog therapy and then labeled as unsuitable patients for interferon therapy. Even if their HBsAg levels dropped to a low level, they were reluctant or not recommended to take interferon again, which caused them to miss out on interferon add-on therapy and clinical cure. Therefore, it is urgent to elucidate the effectiveness of interferon add-on therapy to get clinical cure for these interferon-experienced patients with low HBsAg. The purpose of this study was to investigate whether interferon-experienced patients could achieve the same HBsAg clearance and HBsAg seroconversion rates as interferon-naive patients. Also, the associated factor of HBsAg clearance and seroconversion were aimed to be clarified. 292 patients, including 85 interferon-experienced patients, were enrolled with HBsAg< 1500 IU/ml, HBeAg negative and HBV-DNA negative. And then, peg-interferon α-2b add-on therapy was performed. The results showed that the week 48 HBsAg clearance and seroconversion rates of all patients were 29.8% and 22.0%. There was no statistically significant difference between interferon-experienced and interferon-naive patients in week 48 HBsAg clearance and seroconversion rates, suggesting satisfactory clinical cure of the interferon add-on therapy for interferon-experienced patients. The age, baseline HBsAg, and week 12 HBsAg were negative correlated factors for week 48 HBsAg clearance and seroconversion. Furthermore, the age, baseline HBsAg and week 12 HBsAg for predicting the week 48 HBsAg clearance were cut off at 40.5 years, at 152.0 IU/ml and at 34.99 IU/ml, and for predicting seroconversion were cut off at 40.5 years, at 181.9 IU/ml and at 34.99 IU/ml, correspondingly. Significantly, interferon-experienced patients with low HBsAg were suggested with interferon add-on therapy to achieve clinical cure as soon as possible. This research provided evidences and cut-offs for the interferon add-on therapy against chronic hepatitis B.https://www.frontiersin.org/articles/10.3389/fimmu.2022.997608/fullinterferon add-on therapyclinical cureinterferon-experienced patientschronic hepatitis B patients (CHB)HBsAg |
| spellingShingle | Xiaoan Yang Xiaoan Yang Ka Zhang Ka Zhang Qihuan Xu Qihuan Xu Xin Shu Xin Shu Zhishuo Mo Zhishuo Mo Dongying Xie Dongying Xie Zhiliang Gao Zhiliang Gao Hong Deng Hong Deng Interferon add-on therapy increased clinical cure significantly for interferon-experienced chronic hepatitis B patients with low HBsAg Frontiers in Immunology interferon add-on therapy clinical cure interferon-experienced patients chronic hepatitis B patients (CHB) HBsAg |
| title | Interferon add-on therapy increased clinical cure significantly for interferon-experienced chronic hepatitis B patients with low HBsAg |
| title_full | Interferon add-on therapy increased clinical cure significantly for interferon-experienced chronic hepatitis B patients with low HBsAg |
| title_fullStr | Interferon add-on therapy increased clinical cure significantly for interferon-experienced chronic hepatitis B patients with low HBsAg |
| title_full_unstemmed | Interferon add-on therapy increased clinical cure significantly for interferon-experienced chronic hepatitis B patients with low HBsAg |
| title_short | Interferon add-on therapy increased clinical cure significantly for interferon-experienced chronic hepatitis B patients with low HBsAg |
| title_sort | interferon add on therapy increased clinical cure significantly for interferon experienced chronic hepatitis b patients with low hbsag |
| topic | interferon add-on therapy clinical cure interferon-experienced patients chronic hepatitis B patients (CHB) HBsAg |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2022.997608/full |
| work_keys_str_mv | AT xiaoanyang interferonaddontherapyincreasedclinicalcuresignificantlyforinterferonexperiencedchronichepatitisbpatientswithlowhbsag AT xiaoanyang interferonaddontherapyincreasedclinicalcuresignificantlyforinterferonexperiencedchronichepatitisbpatientswithlowhbsag AT kazhang interferonaddontherapyincreasedclinicalcuresignificantlyforinterferonexperiencedchronichepatitisbpatientswithlowhbsag AT kazhang interferonaddontherapyincreasedclinicalcuresignificantlyforinterferonexperiencedchronichepatitisbpatientswithlowhbsag AT qihuanxu interferonaddontherapyincreasedclinicalcuresignificantlyforinterferonexperiencedchronichepatitisbpatientswithlowhbsag AT qihuanxu interferonaddontherapyincreasedclinicalcuresignificantlyforinterferonexperiencedchronichepatitisbpatientswithlowhbsag AT xinshu interferonaddontherapyincreasedclinicalcuresignificantlyforinterferonexperiencedchronichepatitisbpatientswithlowhbsag AT xinshu interferonaddontherapyincreasedclinicalcuresignificantlyforinterferonexperiencedchronichepatitisbpatientswithlowhbsag AT zhishuomo interferonaddontherapyincreasedclinicalcuresignificantlyforinterferonexperiencedchronichepatitisbpatientswithlowhbsag AT zhishuomo interferonaddontherapyincreasedclinicalcuresignificantlyforinterferonexperiencedchronichepatitisbpatientswithlowhbsag AT dongyingxie interferonaddontherapyincreasedclinicalcuresignificantlyforinterferonexperiencedchronichepatitisbpatientswithlowhbsag AT dongyingxie interferonaddontherapyincreasedclinicalcuresignificantlyforinterferonexperiencedchronichepatitisbpatientswithlowhbsag AT zhilianggao interferonaddontherapyincreasedclinicalcuresignificantlyforinterferonexperiencedchronichepatitisbpatientswithlowhbsag AT zhilianggao interferonaddontherapyincreasedclinicalcuresignificantlyforinterferonexperiencedchronichepatitisbpatientswithlowhbsag AT hongdeng interferonaddontherapyincreasedclinicalcuresignificantlyforinterferonexperiencedchronichepatitisbpatientswithlowhbsag AT hongdeng interferonaddontherapyincreasedclinicalcuresignificantlyforinterferonexperiencedchronichepatitisbpatientswithlowhbsag |